The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients

Sung Joon Hong, Byungha Chung, Jung Soo Kim, Min June Lee, Sun Yoon, Hea Young Oh, Eun Jin Lee, Heon Gwan Lim, Sun Buxiang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: In order to evaluate the effects of GAC, which is the combination of active hexose correlated compound (AHCC) and genistein combined polysaccharide (GCP), we investigated the changes in the biochemical profiles and the quality of life of prostate cancer patients with androgen suppression after the administration of GAC. Materials and methods: Thirty two eligible metastatic prostate cancer patients between the ages of 54 and 84 were enrolled in this study, and they were supplemented with 5g GAC per day (n=23) or placebo (n=9) for a 6 months period. Blood and urine sample analysis were taken and the quality of life (QoL) was assessed using the Visual Analogue Scale (VAS) and the Functional Assessment of Cancer Therapy Scale Questionnaire (FACT-G) at baseline and at post intervention (after 3 and 6 months). Results: Twenty six patients (n=18 in the GAC group and n=8 in the placebo group) completed the 6 months intervention. No statistically significant adverse events were reported by the study participants. GAC had no significant effect on the serum biochemical parameters. However, all 7 GAC-treated hypercholesterolemic patients had their cholesterol level decreased after 3 months treatment (p < 0.02). Results of Comet assay showed significant decreases in tail moment (p < 0.009) and tail length (p < 0.004) at 6 months compared to baseline for the GAC group. Although the results of the VAS were inconsistent, the score for physical well-being was increased in GAC group on the FACT-G analysis (p < 0.05 between baseline and 3 months, respectively). Conclusions: Oral administration of GAC 5g per day for 6 months showed a decrease in DNA damage of blood lymphocytes and in the total serum cholesterol level in hypercholesterolemic patients without any significant influences on the serum biochemical parameters of the metastatic prostate cancer patients. Further studies on the role of GAC are necessary to clarify the advantage of GAC supplementation in prostate cancer patients with androgen suppression.

Original languageEnglish
Pages (from-to)467-474
Number of pages8
JournalKorean Journal of Urology
Volume47
Issue number5
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Prostatic Neoplasms
Quality of Life
Visual Analog Scale
Androgens
Serum
Cholesterol
Placebos
Comet Assay
DNA Damage
Oral Administration
Urine
Lymphocytes
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Hong, Sung Joon ; Chung, Byungha ; Kim, Jung Soo ; Lee, Min June ; Yoon, Sun ; Oh, Hea Young ; Lee, Eun Jin ; Lim, Heon Gwan ; Buxiang, Sun. / The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients. In: Korean Journal of Urology. 2006 ; Vol. 47, No. 5. pp. 467-474.
@article{d58ca87cf8b9405093ecce9d5c157579,
title = "The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients",
abstract = "Purpose: In order to evaluate the effects of GAC, which is the combination of active hexose correlated compound (AHCC) and genistein combined polysaccharide (GCP), we investigated the changes in the biochemical profiles and the quality of life of prostate cancer patients with androgen suppression after the administration of GAC. Materials and methods: Thirty two eligible metastatic prostate cancer patients between the ages of 54 and 84 were enrolled in this study, and they were supplemented with 5g GAC per day (n=23) or placebo (n=9) for a 6 months period. Blood and urine sample analysis were taken and the quality of life (QoL) was assessed using the Visual Analogue Scale (VAS) and the Functional Assessment of Cancer Therapy Scale Questionnaire (FACT-G) at baseline and at post intervention (after 3 and 6 months). Results: Twenty six patients (n=18 in the GAC group and n=8 in the placebo group) completed the 6 months intervention. No statistically significant adverse events were reported by the study participants. GAC had no significant effect on the serum biochemical parameters. However, all 7 GAC-treated hypercholesterolemic patients had their cholesterol level decreased after 3 months treatment (p < 0.02). Results of Comet assay showed significant decreases in tail moment (p < 0.009) and tail length (p < 0.004) at 6 months compared to baseline for the GAC group. Although the results of the VAS were inconsistent, the score for physical well-being was increased in GAC group on the FACT-G analysis (p < 0.05 between baseline and 3 months, respectively). Conclusions: Oral administration of GAC 5g per day for 6 months showed a decrease in DNA damage of blood lymphocytes and in the total serum cholesterol level in hypercholesterolemic patients without any significant influences on the serum biochemical parameters of the metastatic prostate cancer patients. Further studies on the role of GAC are necessary to clarify the advantage of GAC supplementation in prostate cancer patients with androgen suppression.",
author = "Hong, {Sung Joon} and Byungha Chung and Kim, {Jung Soo} and Lee, {Min June} and Sun Yoon and Oh, {Hea Young} and Lee, {Eun Jin} and Lim, {Heon Gwan} and Sun Buxiang",
year = "2006",
month = "1",
day = "1",
doi = "10.4111/kju.2006.47.5.467",
language = "English",
volume = "47",
pages = "467--474",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "5",

}

The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients. / Hong, Sung Joon; Chung, Byungha; Kim, Jung Soo; Lee, Min June; Yoon, Sun; Oh, Hea Young; Lee, Eun Jin; Lim, Heon Gwan; Buxiang, Sun.

In: Korean Journal of Urology, Vol. 47, No. 5, 01.01.2006, p. 467-474.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients

AU - Hong, Sung Joon

AU - Chung, Byungha

AU - Kim, Jung Soo

AU - Lee, Min June

AU - Yoon, Sun

AU - Oh, Hea Young

AU - Lee, Eun Jin

AU - Lim, Heon Gwan

AU - Buxiang, Sun

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: In order to evaluate the effects of GAC, which is the combination of active hexose correlated compound (AHCC) and genistein combined polysaccharide (GCP), we investigated the changes in the biochemical profiles and the quality of life of prostate cancer patients with androgen suppression after the administration of GAC. Materials and methods: Thirty two eligible metastatic prostate cancer patients between the ages of 54 and 84 were enrolled in this study, and they were supplemented with 5g GAC per day (n=23) or placebo (n=9) for a 6 months period. Blood and urine sample analysis were taken and the quality of life (QoL) was assessed using the Visual Analogue Scale (VAS) and the Functional Assessment of Cancer Therapy Scale Questionnaire (FACT-G) at baseline and at post intervention (after 3 and 6 months). Results: Twenty six patients (n=18 in the GAC group and n=8 in the placebo group) completed the 6 months intervention. No statistically significant adverse events were reported by the study participants. GAC had no significant effect on the serum biochemical parameters. However, all 7 GAC-treated hypercholesterolemic patients had their cholesterol level decreased after 3 months treatment (p < 0.02). Results of Comet assay showed significant decreases in tail moment (p < 0.009) and tail length (p < 0.004) at 6 months compared to baseline for the GAC group. Although the results of the VAS were inconsistent, the score for physical well-being was increased in GAC group on the FACT-G analysis (p < 0.05 between baseline and 3 months, respectively). Conclusions: Oral administration of GAC 5g per day for 6 months showed a decrease in DNA damage of blood lymphocytes and in the total serum cholesterol level in hypercholesterolemic patients without any significant influences on the serum biochemical parameters of the metastatic prostate cancer patients. Further studies on the role of GAC are necessary to clarify the advantage of GAC supplementation in prostate cancer patients with androgen suppression.

AB - Purpose: In order to evaluate the effects of GAC, which is the combination of active hexose correlated compound (AHCC) and genistein combined polysaccharide (GCP), we investigated the changes in the biochemical profiles and the quality of life of prostate cancer patients with androgen suppression after the administration of GAC. Materials and methods: Thirty two eligible metastatic prostate cancer patients between the ages of 54 and 84 were enrolled in this study, and they were supplemented with 5g GAC per day (n=23) or placebo (n=9) for a 6 months period. Blood and urine sample analysis were taken and the quality of life (QoL) was assessed using the Visual Analogue Scale (VAS) and the Functional Assessment of Cancer Therapy Scale Questionnaire (FACT-G) at baseline and at post intervention (after 3 and 6 months). Results: Twenty six patients (n=18 in the GAC group and n=8 in the placebo group) completed the 6 months intervention. No statistically significant adverse events were reported by the study participants. GAC had no significant effect on the serum biochemical parameters. However, all 7 GAC-treated hypercholesterolemic patients had their cholesterol level decreased after 3 months treatment (p < 0.02). Results of Comet assay showed significant decreases in tail moment (p < 0.009) and tail length (p < 0.004) at 6 months compared to baseline for the GAC group. Although the results of the VAS were inconsistent, the score for physical well-being was increased in GAC group on the FACT-G analysis (p < 0.05 between baseline and 3 months, respectively). Conclusions: Oral administration of GAC 5g per day for 6 months showed a decrease in DNA damage of blood lymphocytes and in the total serum cholesterol level in hypercholesterolemic patients without any significant influences on the serum biochemical parameters of the metastatic prostate cancer patients. Further studies on the role of GAC are necessary to clarify the advantage of GAC supplementation in prostate cancer patients with androgen suppression.

UR - http://www.scopus.com/inward/record.url?scp=33746437109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746437109&partnerID=8YFLogxK

U2 - 10.4111/kju.2006.47.5.467

DO - 10.4111/kju.2006.47.5.467

M3 - Article

VL - 47

SP - 467

EP - 474

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 5

ER -